Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.
about
Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor VaccinationTowards Targeted Delivery Systems: Ligand Conjugation Strategies for mRNA Nanoparticle Tumor VaccinesRecombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyondSelf-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic NanoparticlesSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapyA Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.Applications of Phosphate Modification and Labeling to Study (m)RNA Caps.Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.Translation, stability, and resistance to decapping of mRNAs containing caps substituted in the triphosphate chain with BH3, Se, and NHEnzymatic synthesis of RNAs capped with nucleotide analogues reveals the molecular basis for substrate selectivity of RNA capping enzyme: impacts on RNA metabolism.Two-headed tetraphosphate cap analogs are inhibitors of the Dcp1/2 RNA decapping complex.A novel route for preparing 5' cap mimics and capped RNAs: phosphate-modified cap analogues obtained via click chemistrymRNAs containing the histone 3' stem-loop are degraded primarily by decapping mediated by oligouridylation of the 3' end.Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format.Developing mRNA-vaccine technologies.Mutant MHC class II epitopes drive therapeutic immune responses to cancer.CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer ImmunotherapySynthesis and evaluation of fluorescent cap analogues for mRNA labelling.Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential.mRNA vaccination as a safe approach for specific protection from type I allergy.Potential therapeutic applications of RNA cap analogs.A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugsmRNA transcript therapy.Lipid-based mRNA vaccine delivery systems.Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.Modified mRNA as a new therapeutic option for pediatric respiratory diseases and hemoglobinopathies.Viral and Synthetic RNA Vector Technologies and Applications.T-cell receptor transfer into human T cells with ecotropic retroviral vectors.Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.mRNA Cancer Vaccines-Messages that Prevail.Mechanism of action of mRNA-based vaccines.Improvement of in vivo expression of genes delivered by self-amplifying RNA using Vaccinia Virus immune evasion proteins.The European Regulatory Environment of RNA-Based Vaccines.Design and Facile Synthesis of New Dinucleotide Cap Analog Containing Both 2' and 3'-OH Modification on M⁷Guanosine Moiety.Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences.Immunotherapy: Cancer vaccine triggers antiviral-type defences.mRNA cap analogues substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging modification that confers resistance to decapping without impairing translationCIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.Reductive Decationizable Block Copolymers for Stimuli-Responsive mRNA Delivery.
P2860
Q26769044-C14AC98C-54FC-42B8-B5BA-A3E3C4240E17Q26773073-E9EBF266-3DC7-4879-A005-7D2C0B764295Q26861563-E5C2C111-983B-4C80-8D92-0FD0D3C5F4DCQ27027078-FBC6003B-38B5-4C61-A653-15945CA214B2Q28005535-AC2F5952-66F2-4321-8914-407E433B2054Q30378994-6E5A28C1-1BFD-46A2-BFC7-9C1A4A101ABAQ33578532-0C425695-F664-4832-B658-70BA86F14136Q34249684-C0C171BA-6BF7-4E4D-85B4-38FEC12CAD57Q34807968-9CDE2A19-3BD4-483A-A226-A31337BF832CQ35005548-F6A2E2B3-00B8-4B66-89F0-940871329ABBQ35908793-FFC4EA76-045A-4E87-BB02-9B42070187A2Q36357301-C6108473-AF9B-4A5A-8EE4-8FBE90EE7979Q36481212-0E57E869-F809-4CE7-8DE0-1B38AB04C1DFQ36673897-F741EC68-D581-426A-AAAC-7534FA60E7A0Q36684597-B4C85FEA-B6D7-4105-8D6C-062CDB357EC7Q36817092-3C02200C-FB95-408F-87B4-BBDBC8FBEDCEQ37130209-1FF0919F-3EED-4CEC-9606-5D593300B92BQ37327958-A2765570-ED3F-42C2-9D3D-8778ECED3A3DQ37523030-319AD22D-21D1-4F44-A7F6-9C28AF95A63DQ37965722-F450C160-FE9F-4958-B7D5-E7D4852CD503Q38116576-5D13780D-74F6-41C6-A305-39192F30A189Q38206520-B868BC8B-AF14-458B-9605-69CF4F691CF1Q38264088-3FE5120F-6570-4AD0-9AFF-579C28E09835Q38300777-3CBB2293-0D71-4020-BEED-A913274F15E7Q38445486-92D33FC5-06CF-4288-9151-B4B785B6E19BQ38641141-C87A19ED-D331-46A7-9256-0179C7A964C4Q38885624-FB79F16A-FC14-4C2D-9E24-BB414C92AE38Q39008906-ACA0F9E1-C1BC-45C8-9D06-CC1E6EC29BBCQ39079371-8B3BDD19-0DE8-4A93-ABCE-58775D8558A6Q39079690-AAB6CD97-5F84-4AD8-B93F-9A450091CB25Q39236800-ED9B720E-7BD0-42CE-A4D7-AC92F209CC41Q39431058-581578E0-8AD8-4E93-B757-2F191D8AAF20Q40055490-C4854632-2C23-4FAB-8D4C-DE497EDD141BQ40405913-E7B3D623-99FD-4E8E-B884-C15376925CF6Q40648279-AF7B019F-A430-4D41-BB05-5275EEDADD7FQ40654970-4E15445B-92CE-48DB-9CC4-271D04C5B147Q40710171-66AFE7D0-FD4F-4CD8-B421-F0D89CEED5AEQ41630115-BCE78AFF-B794-4A23-B79B-1C3E14B75511Q42586718-A45E9266-1854-4057-8F2A-39B79A32460EQ42811744-82B55817-931B-4EDF-9849-3FA98F974817
P2860
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@en
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@nl
type
label
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@en
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@nl
prefLabel
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@en
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@nl
P2093
P2860
P50
P356
P1433
P1476
Phosphorothioate cap analogs i ...... rior immune responses in vivo.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2010.52
P577
2010-04-22T00:00:00Z
P6179
1049468073